Loading
The US national trial that uses a blood test for leftover tumour DNA to decide who gets less chemotherapy and who gets more after stage III colon cancer surgery, with both questions randomised.
CIRCULATE-US (NRG-GI008) is the NRG Oncology phase 2/3 trial in resected stage III colon cancer. Patients are tested with Signatera after surgery; ctDNA-negative patients are randomised between immediate chemotherapy and surveillance with treatment on conversion, and ctDNA-positive patients are randomised between standard mFOLFOX6 or CAPOX and intensified mFOLFIRINOX. The registry lists an estimated 1,912 participants, a start on 8 July 2022, recruiting status, primary completion on 10 March 2029 and study completion on 10 March 2030. It is the US counterpart of CIRCULATE-Japan and TRACC and the trial most likely to settle whether escalation helps ctDNA-positive colon cancer.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna-roadmap.
Shares Natera, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Signatera.
Shares ctDNA MRD → adjuvant therapy decision, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Signatera.
Shares Natera, Tumour-informed versus tumour-naive ctDNA assays, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), Signatera.
Shares ctDNA MRD → adjuvant therapy decision, Tumour-informed versus tumour-naive ctDNA assays, DYNAMIC, Signatera.
Shares Tumour-informed versus tumour-naive ctDNA assays, DYNAMIC, Signatera, Minimal / molecular residual disease (MRD).